Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles

• DOI: 10.2147/ijn.s152485
• Publication Date: 2018-01-08T18:29:13Z
• Authors: Wei Zhang; Yunmei Song; Preethi Eldi; Xiuli Guo; John Hayball; Sanjay Garg; Hugo Albrecht
• Keywords: Male; Medicine (General); Cell Survival; GRPR; Antineoplastic Agents; Docetaxel; 03 medical and health sciences; GPCR; R5-920; Drug Delivery Systems; 0302 clinical medicine; International Journal of Nanomedicine; ELP-GRP; Cell Line, Tumor; micelle; docetaxel; Humans; Molecular Targeted Therapy; Micelles; Original Research; Prostatic Neoplasms; prostate cancer; Elastin; 3. Good health; Receptors, Bombesin; liposome; Liposomes; Nanoparticles; Taxoids; Peptides; Hydrophobic and Hydrophilic Interactions

Prostate cancer cells frequently overexpress the gastrin-releasing peptide receptor, and various strategies have been applied in preclinical settings to target this receptor for the specific delivery of anticancer compounds. Recently, elastin-like polypeptide (ELP)-based self-assembling micelles with tethered GRP on the surface have been suggested to actively target prostate cancer cells. Poorly soluble chemotherapeutics such as docetaxel (DTX) can be loaded into the hydrophobic cores of ELP micelles, but only limited drug retention times have been achieved. Herein, we report the generation of hybrid ELP/liposome nanoparticles which self-assembled rapidly in response to temperature change, encapsulated DTX at high concentrations with slow release, displayed the GRP ligand on the surface, and specifically bound to GRP receptor expressing PC-3 cells as demonstrated by flow cytometry. This novel type of drug nanocarrier was successfully used to reduce cell viability of prostate cancer cells in vitro through the specific delivery of DTX.